Evidence map›Paper›PMID 26506094›Full record

ArticlePloS one2015

Role of LRP1 and ERK and cAMP Signaling Pathways in Lactoferrin-Induced Lipolysis in Mature Rat Adipocytes.

Keiko Ikoma-Seki, Kanae Nakamura, Satoru Morishita, Tomoji Ono, Keikichi Sugiyama, Hoyoku Nishino, Hisashi Hirano, Michiaki Murakoshi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. GRK5 is required for adipocyte differentiation through ERK activation.International journal of obesity (2005) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Lactoferrin as a Human Genome "Guardian"-An Overall Point of View.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Keiko Ikoma-SekiResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan; Advanced Medical Research Center, Yokohama City University, Kanagawa, Japan.
Kanae NakamuraResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan.
Satoru MorishitaResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan.
Tomoji OnoResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan; Advanced Medical Research Center, Yokohama City University, Kanagawa, Japan.
Keikichi SugiyamaResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan; Ritsumeikan University, Shiga, Japan.
Hoyoku NishinoKyoto Prefectural University of Medicine, Kyoto, Japan; Ritsumeikan University, Shiga, Japan.
Hisashi HiranoAdvanced Medical Research Center, Yokohama City University, Kanagawa, Japan.
Michiaki MurakoshiResearch and Development Headquarters, Lion Corporation, Kanagawa, Japan; Advanced Medical Research Center, Yokohama City University, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yokohama City University · JPLion Corporation (Japan) · JPKyoto Prefectural University of Medicine · JPRitsumeikan University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactoferrin (LF) is a multifunctional glycoprotein present in milk. A clinical study showed that enteric-coated bovine LF tablets decrease visceral fat accumulation. Furthermore, animal studies revealed that ingested LF is partially delivered to mesenteric fat, and in vitro studies showed that LF promotes lipolysis in mature adipocytes. The aim of the present study was to determine the mechanism underlying the induction of lipolysis in mature adipocytes that is induced by LF. To address this question, we used proteomics techniques to analyze protein expression profiles. Mature adipocytes from primary cultures of rat mesenteric fat were collected at various times after exposure to LF. Proteomic analysis revealed that the expression levels of hormone-sensitive lipase (HSL), which catalyzes the rate-limiting step of lipolysis, were upregulated and that HSL was activated by protein kinase A within 15 min after the cells were treated with LF. We previously reported that LF increases the intracellular concentration of cyclic adenosine monophosphate (cAMP), suggesting that LF activates the cAMP signaling pathway. In this study, we show that the expression level and the activity of the components of the extracellular signal-regulated kinase (ERK) signaling pathway were upregulated. Moreover, LF increased the activity of the transcription factor cAMP response element binding protein (CREB), which acts downstream in the cAMP and ERK signaling pathways and regulates the expression levels of adenylyl cyclase and HSL. Moreover, silencing of the putative LF receptor low-density lipoprotein receptor-related protein 1 (LRP1) attenuated lipolysis in LF-treated adipocytes. These results suggest that LF promoted lipolysis in mature adipocytes by regulating the expression levels of proteins involved in lipolysis through controlling the activity of cAMP/ERK signaling pathways via LRP1.

Indexed as

AdipocytesAnimalsCattleCyclic AMPGene Expression RegulationIntra-Abdominal FatLactoferrinLipolysisLow Density Lipoprotein Receptor-Related Protein-1MAP Kinase Signaling SystemProteomicsRatsSterol EsteraseCyclic AMPLactoferrinLow Density Lipoprotein Receptor-Related Protein-1Sterol Esterase

Identifiers

PMID26506094
PMCPMC4623961
OpenAlexW2256639710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.